Yes, combining Orgovyx (relugolix) with Xtandi (enzalutamide) is superior to Orgovyx alone for metastatic prostate cancer
For patients with metastatic prostate cancer, you should use combination therapy with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) rather than ADT alone. The evidence strongly supports treatment intensification beyond ADT monotherapy.
Understanding the Treatment Landscape
First, let me clarify the terminology: Orgovyx (relugolix) is an oral form of ADT - it's not a treatment that stands alone as optimal therapy for metastatic disease 1. Think of it as a modern replacement for traditional injectable ADT like leuprolide. Xtandi (enzalutamide) is an ARPI that blocks testosterone's effects at the cellular level 2.
The question you're really asking is: Should you use ADT alone versus ADT plus an ARPI?
The Clear Answer: Combination Therapy Wins
Current guidelines strongly recommend ADT plus an ARPI (like enzalutamide, apalutamide, or abiraterone) as standard treatment for metastatic hormone-sensitive prostate cancer 3. These represent four separate standards of care, each superior to ADT alone.
The Evidence for Combination Therapy:
Enzalutamide plus ADT demonstrated significant survival benefits in the ENZAMET trial, showing improvements in PSA progression-free survival, clinical progression-free survival, and overall survival compared to ADT alone 3. The recommended regimen is enzalutamide 160 mg daily with ADT 3.
The benefit applies broadly: This includes patients with newly diagnosed metastatic disease AND those who previously received surgery or radiation for localized disease 3.
All ARPIs show similar benefits: Abiraterone, enzalutamide, and apalutamide each demonstrate strong evidence for improving survival when combined with ADT 3.
Why Orgovyx Specifically?
Orgovyx offers advantages as the ADT component:
- Rapid testosterone suppression without the initial testosterone surge seen with traditional injectable ADT 4, 5
- 54% lower risk of major cardiovascular events compared to leuprolide 4
- Faster testosterone recovery after treatment stops (mean 288 ng/dL at 90 days vs 58.6 ng/dL with leuprolide) 4
- Oral administration improves convenience 5, 6
The Triplet Option: Even More Aggressive
For patients with high-volume metastatic disease who are fit for chemotherapy, the newest data supports triplet therapy: ADT + docetaxel + an ARPI (either darolutamide or abiraterone) 7, 8.
Darolutamide + docetaxel + ADT (the ARASENS trial):
- Reduced death risk by 32% (HR 0.68) 7
- 4-year survival: 62.7% vs 50.4% with ADT + docetaxel alone 7
- FDA approved August 2022 7
- Similar toxicity to doublet therapy 7
Abiraterone + docetaxel + ADT (the PEACE-1 trial):
- Reduced death risk by 25% (HR 0.75) in the docetaxel-treated population 7
- Improved radiographic progression-free survival (HR 0.50) 7
Critical Caveats
ADT alone should only be used in vulnerable patients who cannot tolerate treatment intensification 9. This is a strong statement from current guidelines.
Important limitation: The guidelines explicitly state that using these agents in combination or in series has not been adequately studied and cannot be routinely recommended 3. However, this refers to combining multiple ARPIs together or with chemotherapy beyond the studied triplet regimens.
Practical Algorithm
For newly diagnosed metastatic prostate cancer:
Assess fitness for chemotherapy and disease volume (high-volume = 4+ bone metastases with ≥1 outside spine/pelvis, OR visceral metastases)
If fit for chemotherapy + high-volume disease:
If not fit for chemotherapy OR low-volume disease:
If too frail for intensified therapy:
- Only then: ADT alone 9
For the ADT component specifically, Orgovyx offers advantages over injectable options, particularly regarding cardiovascular safety and convenience 4, 5, 6.
Bottom Line
Never use ADT (Orgovyx) alone if the patient can tolerate combination therapy. The survival benefit of adding an ARPI like Xtandi is substantial and well-established. For fit patients with high-volume disease, consider triplet therapy with chemotherapy added to the combination.